Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unicorn: Single-drug Chemo + Immunotherapy in Elderly Metastatic NSCLC
NCT06032052Phase 2Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Feb 2024
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, penpulimab, camrelizumab, tislelizumab, sintilimab in non-small cell lung cancer (NSCLC), sponsored by Hubei Cancer Hospital. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06032052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06032052.